Mainstream

Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide

Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide

Post Contentnvo, lly, ivbiy, ivbxfRead More

You might also be interested in reading Thai SEC forced to clarify proposed crypto rules after public backlash.

June 30, 2025
In Mainstream